FDA Inspection 1223069 — Anna Gauarashvili
The FDA completed an inspection of Anna Gauarashvili on November 2, 2023 in Tbilisi. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 2, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Tbilisi (Georgia)
Additional Details
Clinical Investigator (CI)